Methotrexate Injection Shortage
Last Updated: March 13, 2024
Status: Current
Products Affected - Description
-
- Methotrexate injection, Accord, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 16729-0277-03
- Methotrexate injection, Accord, 25 mg/mL, 2 mL preservative-free vial, 1 count, NDC 16729-0277-30
- Methotrexate injection, Hikma, 25 mg/mL, 2 mL preservative-free vial, 10 count, NDC 00143-9519-10
- Methotrexate, Hikma, 1 gram, vial, 1 count, NDC 00143-9830-01
- Methotrexate injection, Pfizer, 25 mg/mL, 2 mL (with preservative) vial, 5 count, NDC 61703-0350-38
Reason for the Shortage
-
- Accord has methotrexate injection on shortage due to manufacturing delays.
- Fresenius Kabi has methotrexate injection available.
- Pfizer has methotrexate injection on back order due to increased demand.
- Teva has methotrexate injection on back order due to increased demand.
- Hikma has methotrexate injection on back order due to increased demand.
Available Products
-
- Methotrexate injection, Accord, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 16729-0277-35
- Methotrexate injection, Fresenius Kabi, 25 mg/mL, 10 mL (with preservative) vial, 1 count, NDC 63323-0123-10
- Methotrexate, Fresenius Kabi, 1 gram, vial, 1 count, NDC 63323-0122-50
- Methotrexate injection, Pfizer, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 61703-0408-41
- Methotrexate injection, Teva, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 00703-3675-01
- Methotrexate injection, Teva, 25 mg/mL, 2 mL preservative-free vial, 1 count, NDC 00703-3671-01
- Methotrexate injection, Teva, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 00703-3678-01
Estimated Resupply Dates
-
- Accord has methotrexate 25 mg/mL 2 mL and 10 mL preservative-free vials on back order and the company cannot estimate a release date.
- Hikma has methotrexate 25 mg/mL 2 mL preservative-free vials and 1 gram lyophilized powder vials on allocation.
- Pfizer has methotrexate 25 mg/mL 2 mL vials available in limited supply.
Alternative Agents & Management
-
- The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for methotrexate.
- Consider evaluating the health-care system's total supply of methotrexate before beginning patients on combination chemotherapy regimens containing methotrexate. If adequate supplies are not available, select an alternative regimen.
- Reserve preservative-free methotrexate for intrathecal doses.
- Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations and other specialists for non-oncology uses.
- Use oral methotrexate whenever possible for non-oncology indications.
Updated
Updated March 13, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 2, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.